Ocular Therapeutix (OCUL) Prepaid Assets (2013 - 2026)
Ocular Therapeutix (OCUL) posted quarterly Prepaid Assets of $11.7 million for Q2 2026, up 33.09% year-over-year from $8.8 million in Q2 2025, and up 4.34% on a QoQ basis from $11.2 million in Q1 2026.
Ocular Therapeutix (OCUL) Prepaid Assets (2013 - 2026) Analysis & Trends
Ocular Therapeutix has reported Prepaid Assets for 14 years, with the latest figure at $11.7 million in Q2 2026.
- Prepaid Assets for Q2 2026 came in at $11.7 million, up 33.09% year-over-year; the trailing twelve-month figure through Jun 2026 was $11.7 million (up 33.09% YoY), and the FY2025 annual result was $10.9 million, down 19.34% from the prior year.
- Prepaid Assets advanced to $11.7 million in Q2 2026, from $11.2 million in the prior quarter.
- Over five years, Prepaid Assets peaked at $13.5 million in Q4 2024 and troughed at $3.3 million in Q3 2022.
- A 5-year average of $7.7 million and a median of $7.7 million in 2023 frame the typical range for Prepaid Assets.
- The widest annual swing landed in 2024, when Prepaid Assets soared 170.49%; it then slumped 39.53% in 2025.
- A 5-year view of Prepaid Assets shows it stood at $4.0 million in 2022, then soared by 93.5% to $7.8 million in 2023, then soared by 72.66% to $13.5 million in 2024, then retreated by 19.34% to $10.9 million in 2025, then gained by 7.78% to $11.7 million in 2026.
- Per Business Quant data, the three most recent Prepaid Assets figures were $11.7 million in Q2 2026, $11.2 million in Q1 2026, and $10.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Ocular Therapeutix | 2.20 Bn | 2.20 Bn | 11.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.70 Mn |
| Mar 31, 2026 | 11.21 Mn |
| Dec 31, 2025 | 10.86 Mn |
| Sep 30, 2025 | 7.95 Mn |
| Jun 30, 2025 | 8.79 Mn |
| Mar 31, 2025 | 9.52 Mn |
| Dec 31, 2024 | 13.46 Mn |
| Sep 30, 2024 | 13.15 Mn |
| Jun 30, 2024 | 6.12 Mn |
| Mar 31, 2024 | 7.67 Mn |
| Dec 31, 2023 | 7.79 Mn |
| Sep 30, 2023 | 4.86 Mn |
| Jun 30, 2023 | 4.59 Mn |
| Mar 31, 2023 | 4.75 Mn |
| Dec 31, 2022 | 4.03 Mn |
| Sep 30, 2022 | 3.32 Mn |
| Jun 30, 2022 | 3.80 Mn |
| Mar 31, 2022 | 4.67 Mn |
| Dec 31, 2021 | 4.75 Mn |
| Sep 30, 2021 | 3.88 Mn |